§ COMPOUND PROFILE · INDEPENDENT RESEARCH575 TESTS · AVG 99.57% · 219 SHOPS
◆ COMPOUND · WEIGHT LOSS & METABOLIC
Weight Loss & Metabolic

Tirzepatide

Dual GIP/GLP-1 receptor agonist developed by Eli Lilly, approved for type 2 diabetes (Mounjaro®) and chronic weight management (Zepbound®).

Peptigrity tracks Tirzepatide across 219 shops with 575 independent lab tests and an average HPLC purity of 99.57%.

Avg. HPLC purity99.57%
Lab tests on file575
Shops selling219

Lab test results

575 tests · AVG 99.57%
◆ CROSS-SHOP COMPARISON · SORTED BY DATE12 of 575 SHOWN
Date
Shop
Purity
Qty (labeled → tested)
Endotoxins
Lab
Aug 10, 2026
99.83%
60mg69.01mg+15%
-
May 21, 2026
99.79%
10mg12.03mg+20.3%
-
May 21, 2026
99.71%
30mg32.001mg+6.7%
-
May 21, 2026
99.85%
60mg63.042mg+5.1%
-
May 19, 2026
99.84%
20mg21.998mg+10%
-
May 19, 2026
98.39%
30mg36.876mg+22.9%
-
May 19, 2026
99.69%
30mg31.095mg+3.6%
-
May 19, 2026
99.73%
60mg65.064mg+8.4%
-
May 15, 2026
99.66%
100mg110.99mg+11%
-
May 13, 2026
99.96%
30mg32.25mg+7.5%
PASS (≤0.5 EU/mL)
May 7, 2026
99.85%
30mg32.751mg+9.2%
-
Apr 30, 2026
99.89%
60mg60.792mg+1.3%
-

Shops selling Tirzepatide

219 verified · top 6 shown

What Is Tirzepatide

Mechanism & research

Dual GIP/GLP-1 receptor agonist developed by Eli Lilly, approved for type 2 diabetes (Mounjaro®) and chronic weight management (Zepbound®).

Tirzepatide vs other peptides

Same category · Lab-verified
Compound
Mechanism
Avg purity
Tests
Compare
Tirzepatide→ This page
GLP-1 / GIP dual-agonist
99.57%
575
GLP-1 / GIP / Glucagon triple-agonist
99.65%
610
GLP-1 receptor agonist
99.65%
238
Mitochondrial-derived metabolic peptide
99.43%
233
Long-acting amylin receptor agonist
99.64%
161
HGH fragment for lipolysis
99.21%
79
Compared on independent lab purityBrowse all Weight Loss & Metabolic

Related peptides

Same category
● COMMUNITY VERIFICATION

Have a lab test for Tirzepatide?

Every submitted test helps the community verify purity across brands. Free, fast, independent.

Submit a test →